T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic...

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with increasing incidence and high mortality.
• Etiology involves human Merkel cell polyomavirus (80%) or UV-induced mutations (20%).
• Standard metastatic MCC treatment includes anti-PD-1/-PD-L1 immune checkpoint inhibitors (ICI).

Purpose of the Study:

• To review current and future ICI therapies for MCC.
• To present alternative immunotherapeutic options.
• To discuss the significance of T-cell responses in MCC treatment.

Main Methods:

• Literature review of current research on MCC treatment.
• Analysis of immune checkpoint inhibitor efficacy and limitations.
• Exploration of alternative immunotherapies and T-cell-mediated mechanisms.

Main Results:

• ICI therapies show improved response rates and duration compared to chemotherapy for metastatic MCC.
• Approximately 50% of patients exhibit resistance or immune-related adverse events (irAEs) to ICI.
• Alternative options like cytokines, pro-inflammatory agents, and therapeutic vaccines show promise.
• Tumor-infiltrating CD8+ T-cells and their phenotype are critical for ICI effectiveness and clinical outcomes.

Conclusions:

• ICI are a cornerstone in metastatic MCC treatment, but challenges like resistance and irAEs persist.
• Understanding and modulating T-cell responses are vital for enhancing MCC treatment efficacy.
• Future strategies should focus on optimizing ICI, exploring novel immunotherapies, and leveraging T-cell-based approaches.